Cite
HARVARD Citation
Elbitar, S. et al. (n.d.). Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert opinion on therapeutic patents. pp. 1377-1392. [Online].